Nurix Therapeutics, Inc.

NASDAQ:NRIX

Biotechnology

Healthcare
$14.10 +0.85%

+$0.15 today

Market cap
$1.54B
Beta
1.87
P/E (TTM)
-6.4
EPS (TTM)
-$2.68
52W Low $8.20High $22.50

Volume 2.79M

Average 1.74M

NRIX Depreciation & Amortization

Non-cash asset write-downs added back to net income because no cash left the business.

Nurix Therapeutics, Inc.NASDAQ: NRIX

Depreciation & Amortization · Q3 FY2026 · quarter ended Aug 2026

Depreciation & amortization declines year over year

Q3 FY2026 depreciation & amortization of $3.62M fell 27.7% year over year, behind the -14.3% change in trailing-twelve-month depreciation & amortization. Sequentially, it fell 6.1% from the prior quarter. Over 3 fiscal years it compounded at +20.4% a year.

Context

  • Depreciation & amortization amounted to 22.5% of revenue in FY2025, down 7.7 pp from a year earlier.
  • Depreciation & amortization increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -27.7% toward the trailing-twelve-month pace of -14.3%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterAug 2026
$3.62M-6.1% QoQ
Last fiscal yearNov 2025
$18.86M+14.8% YoY
LTMAug 2026
$15.87M-14.3% YoY
Depreciation & Amortization past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-27.7%——
1 year+14.8%——
3-year CAGR+20.4%——
5-year CAGR——
10-year CAGR——

Depreciation & Amortization history

USD · from the cash flow

Latest · FY2025
18.86M USD
Year-over-year change
+14.8%
4-year CAGR
+32.7%

Depreciation & Amortization vs competitors

How NRIX compares with its peers on the latest reported figures

  • NRIX's LTM Aug 2026 depreciation & amortization of $15.87M is the 2nd largest of the 8 companies compared; the peer median is $2.43M.
  • Its year-over-year change of -14.3% is the 6th highest of 8, against a peer median of +1.6%.
  • Depreciation & amortization amounts to 2.3% of revenue for NRIX, versus a peer median of 3.4%.
NRIX Competitors Peer median
Depreciation & Amortization for NRIX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
RVMDRevolution Medicines, Inc.LTM Jun 2026$18.08M +31.1%+19.7%—
NRIXNurix Therapeutics, Inc.LTM Aug 2026$15.87M -14.3%+20.4%2.3%
KYMRKymera Therapeutics, Inc.LTM Jun 2026$8.23M +1.6%+40.8%7.8%
CCCCC4 Therapeutics, Inc.LTM Mar 2026$3.38M +84.9%+5.3%9.7%
KURAKura Oncology, Inc.LTM Mar 2026$2.43M +183.7%—3.4%
RIGLRigel Pharmaceuticals, Inc.LTM Mar 2026$2.41M -1.0%+34.3%0.8%
TNGXTango Therapeutics, Inc.LTM Sep 2026$1.79M -26.2%+12.4%—
SNDXSyndax Pharmaceuticals, Inc.LTM Mar 2026$102K -2140.0%-43.3%0.0%
Peer median (excluding NRIX) $2.43M+1.6%+16.0%3.4%

Competitors are the stored peer set for NRIX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Nov 2021
FY2022
Nov 2022
FY2023
Nov 2023
FY2024
Nov 2024
FY2025
Nov 2025
Net Income(117.19M)(180.36M)(143.95M)(193.57M)(264.46M)
Depreciation & Amortization6.08M10.81M13.65M16.43M18.86M
Deferred Income Tax00000
Stock-Based Compensation15.8M28.13M33.67M33.93M37.97M
Change in Working Capital9.11M(19.02M)20.12M(18.4M)(31.6M)
Accounts Receivables(6M)6M000
Inventory6.77M0000
Accounts Payables1.59M85K1.61M5.21M(630K)
Other Working Capital6.75M(25.11M)18.51M(23.61M)(30.97M)
Other Non-Cash Items1.83M636K(4.87M)(10.97M)(10.23M)
Operating Cash Flow(84.37M)(159.81M)(81.37M)(172.58M)(249.47M)
Capital Expenditures(5.66M)(12.24M)(8.4M)(9.27M)(14M)
Acquisitions (Net)102.59M(39.44M)000
Purchases of Investments(348.5M)(239.37M)(246.33M)(707.95M)(455.69M)
Sales of Investments245.91M278.81M323.04M459.51M617.54M
Other Investing Activities(102.59M)39.44M000
Investing Cash Flow(108.25M)27.2M68.3M(257.71M)147.85M
Debt Repayment00000
Common Stock Issued150.16M19.4M3.22M478.5M238.64M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities3.73M97.79M07.17M0
Financing Cash Flow153.88M117.19M3.22M485.67M238.64M
Effect of Forex Changes0000(67K)
Net Change in Cash(38.73M)(15.42M)(9.85M)55.37M137.03M
Free Cash Flow(90.03M)(172.05M)(89.77M)(181.86M)(263.47M)

Nurix Therapeutics, Inc.

NASDAQ:NRIX

Intrinsic Alpha fair value

Locked

Current Price

$14.10

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.